Ipsen (IPN) H2 2024 earnings summary

Executive summary

• Total sales grew 9.9% in 2024, with all therapeutic areas contributing; rare diseases up 67.4%, neuroscience up 9.2%, oncology up 7.3%.

• Core operating margin reached 32.6%, with core operating income up 10.8% to over €1.1 billion.

• IFRS net profit declined 46.3% to €347 million, mainly due to a €281 million impairment loss on Sohonos.

• Major pipeline progress included FDA and EMA approvals for Onivyde, Iqirvo, and Kayfanda, plus multiple new partnerships in oncology and neuroscience.

• Free cash flow increased by 8.9% to €774 million, with a net cash position of €160 million and €2.3 billion available for external innovation.

Financial highlights

• Total sales: €3,401 million (+9.9% CER, +8.7% reported); core operating income: €1,109 million (+10.8%); free cash flow: €774 million (+8.9%).

• Core EPS grew 12.3% to €10.27; dividend per share: €1.20 (flat year-over-year).

• Gross margin decreased by 0.6 percentage points, mainly due to a one-off payment in 2023.

• R&D costs rose to 20.2% of sales, reflecting increased investment in pipeline and external innovation.

• SG&A costs reduced to 34.4% of sales (down 2.2 pts), benefiting from efficiency programs.

Outlook and guidance

• 2025 guidance: total sales growth above 5% at constant rates, core operating margin above 30%.

• Guidance assumes Somatuline sales erosion due to increased generic competition in the US and Europe.

• Accelerated growth expected from ex-Somatuline portfolio and continued investment in R&D and launches.

• Margin expected to be higher in H1 and lower in H2 due to cost phasing and Somatuline erosion.

• Midterm margin outlook to reach at least 32% by 2027.